<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625781</url>
  </required_header>
  <id_info>
    <org_study_id>061018-237</org_study_id>
    <secondary_id>TIP protocol Medscinet</secondary_id>
    <nct_id>NCT00625781</nct_id>
  </id_info>
  <brief_title>Treatment of Impaired Glucose Tolerance in Pregnancy</brief_title>
  <acronym>TIP</acronym>
  <official_title>Randomized Controlled, Multicenter Study Evaluating Treatment of Glucose Intolerance in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala-Örebro Regional Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Örebro County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if treatment (insulin or diet) of pregnant women
      with impaired glucose tolerance (75-g OGTT with a fasting P-gluc &lt;7.0 mmol/l and 2 h P-gluc
      &gt;10.0 and &lt;12.2 mmol/l) close to normoglycemia reduces children´s birth weight and neonatal
      morbidity. There will be a focus on treatment according to specific goals and separate
      follow-up regimes for the children and women post partum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perinatal morbidity and intrauterine growth</measure>
    <time_frame>1 year post partum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Children´s future health</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Fetal Macrosomia</condition>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGT randomized to treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>IGT randomized to &quot;no treatment&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart and Insulin human (isophane)</intervention_name>
    <description>Insulin treatment if fasting p-glucose &gt;5.0 mmol/l or post meal value &gt;6.5 mmol/l according to study protocol.</description>
    <arm_group_label>B2</arm_group_label>
    <other_name>NovoRapid FlexPen, A10AB05</other_name>
    <other_name>Insulatard FlexPen, A10AC01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with 75g OGTT result : fasting capillary plasma &lt;=7.0 mmol/l and/or 2 h value &gt;=
             12.2 mmol/l

        Exclusion Criteria:

          -  Multiple pregnancy

          -  Pregestational Diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Hanson, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>Uppsala Academic Hospital , Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Östlund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Örebro County</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Örebro County</investigator_affiliation>
    <investigator_full_name>Helena Fadl</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Gestational diabetes mellitus</keyword>
  <keyword>Impaired glucose Tolerance</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Fetal macrosomia</keyword>
  <keyword>Treatment</keyword>
  <keyword>Perinatal morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Fetal Macrosomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

